- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | Bioventus präsentiert Wachstumsstrategie und Turnaround-Plan auf Morgan Stanley Konferenz | 1 | Investing.com Deutsch | ||
| 12.08. | Bioventus auf Canaccord-Konferenz: Strategischer Wachstumspfad | 1 | Investing.com Deutsch | ||
| 11.08. | Cantor Fitzgerald reiterates Overweight rating on Bioventus stock | 1 | Investing.com | ||
| 07.08. | Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance | 3 | Seeking Alpha | ||
| 06.08. | Bioventus Non-GAAP EPS of $0.21, revenue of $147.7M | 1 | Seeking Alpha | ||
| 06.08. | Bioventus Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.08. | Bioventus enters into a new $400M credit agreement, lowering interest expenses | 2 | Seeking Alpha | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 04.08. | Bioventus, Inc.: Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity | 1 | GlobeNewswire (USA) | ||
| 31.07. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Bioventus erhält FDA-Zulassung für zwei neue Geräte zur Schmerztherapie | 1 | Investing.com Deutsch | ||
| 30.07. | Bioventus receives FDA clearance for two pain management devices | 2 | Investing.com | ||
| 30.07. | Bioventus gets FDA nod for pain management devices | 1 | Seeking Alpha | ||
| 30.07. | Bioventus wins FDA nod for duo of next-gen peripheral nerve stim products | 2 | MassDevice | ||
| 30.07. | Bioventus, Inc.: Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products | 271 | GlobeNewswire (Europe) | DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug... ► Artikel lesen | |
| 29.07. | Bioventus, Inc.: Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 16.07. | Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating | 2 | Insider Monkey | ||
| 07.07. | Cantor Fitzgerald initiates Bioventus stock with Overweight rating on growth potential | 1 | Investing.com | ||
| 04.06. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Bioventus reiterates 2025 guidance with focus on growth and profitability | 1 | Seeking Alpha | ||
| 06.05. | Bioventus Q1 2025 slides: 5% organic growth despite revenue decline, maintains guidance | 2 | Investing.com |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 20,050 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | 0,00 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
| BEAM THERAPEUTICS | 26,340 | 0,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | 0,00 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| LENZ THERAPEUTICS | 38,740 | 0,00 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| BIONTECH | 89,45 | +1,82 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| ARCELLX | 86,80 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,45 | 0,00 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 49,740 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| COGENT BIOSCIENCES | 16,250 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BICARA THERAPEUTICS | 17,780 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 8,240 | 0,00 % | Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy | U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim... ► Artikel lesen |
BIOVENTUS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.